CA-AG v. Teva

Teva allegedly promoted potent, rapid-onset fentanyl products for use by non-cancer patients; deceptively marketed opioids by downplaying the risk of addiction and overstating their benefits, including encouraging the myth that signs of addiction are actually “pseudoaddiction” treated by prescribing more opioids; and failed to comply with suspicious order monitoring requirements along with its distributor, Anda, according to CA-AG.

Summary generated from official California Attorney General press release